A fog of uncertainty hangs thickly in the air. Manufacturers find themselves wringing their hands in the aftermath of sweeping layoffs and shifting policies at the Department of Health and Human Services, the FDA, and elsewhere.
The article that follows shines a spotlight on a single program emblematic of this collective anxiety: the pediatric priority review voucher initiative, now among the earliest casualties of fiscal cutbacks. One might expect that a program championing treatments for rare and orphan pediatric diseases would win easy favor in the political arena—yet even such causes can be ground to dust in all the political meat grinding.
The fate of voucher programs at large remains uncertain, casting a long shadow. The article notes a particular complication: “Despite widespread support, the priority review program faces some opposition – especially regarding companies redeeming vouchers for drugs outside the rare disease sphere; critics maintain these incentives should be reserved solely for treatments targeting rare conditions.”
Ultimately, as ever, it all boils down to finances. With the program’s future hanging in the balance, investors hesitate, less willing to commit resources amidst the ongoing uncertainty.
——————————————————————————————
FDA Layoffs and Priority Review Program’s Lapse Disrupt Rare Disease Pipeline
The expiration of the FDA’s pediatric priority review voucher program is creating uncertainty for rare disease drug developers.
